Outcome in patients with peripheral T-cell lymphoma treated with pralatrexate, single center experience

Authors : Aydan AKDENİZ, Nurcan YILMAZ, Mahmut Bakır KOYUNCU, Anıl TOMBAK

Pages : 20-24

Doi:10.46310/tjim.984313

View : 16 | Download : 12

Publication Date : 2022-01-29

Article Type : Research Paper

Abstract :Background: Peripheral T-cell lymphoma insert ignore into journalissuearticles values(PTCL); accounts for 10-15% of all non-Hodgkin lymphomas. Five-year overall survival is very poor in all subtypes except in ALK positive anaplastic large cell lymphomas insert ignore into journalissuearticles values(ALCL);. Patients in relapsed-refractory insert ignore into journalissuearticles values(RR); setting, treatment options are very limited, particularly in patients with poor performance or advanced age. Pralatrexate has been shown to improve remission and survival rates in RR PTCL. We aimed to evaluate the response rates, efficacy and adverse event profile of pralatrexate used in RR PTCL in our center. Material and Methods: Patients followed in hematology department of Mersin University with the diagnosis of RRPTCL and treated with pralatrexate were included in study. Their demographical and clinical data were documented. Response to treatment with pralatrexate was evaluated. Results: Median follow up time was 14 months and mean age at diagnosis was 50.6 insert ignore into journalissuearticles values(±17.9); in totally 11 patients. Patients received median 2 cycles of pralatrexate. Six patients were refractory to treatment while 5 patients achieved at least partial remission. Conclusions: PTCL has the worst prognosis among all types of lymphomas. Cure rates are still low and new therapeutic options are needed.
Keywords : Non hodgkin lymphoma, Peripheral T cell lymphoma, pralatrexate